Publications by authors named "V Saglimbene"
Article Synopsis
- Diabetes significantly increases the risk of chronic kidney disease (CKD) and cardiovascular issues, with about one in three adults with diabetes also having CKD.
- SGLT2 inhibitors show promise in improving kidney and heart health for individuals with CKD and diabetes, but ongoing research is needed to evaluate their effectiveness.
- This review examines randomised controlled trials of SGLT2 inhibitors to provide a comprehensive assessment of their benefits and risks for patients with CKD and diabetes.
Objective: Hypertension affects 50-90% of kidney transplant recipients and is associated with cardiovascular disease and graft loss. We aimed to evaluate the comparative benefits and harms of blood pressure lowering agents in people with a functioning kidney transplant.
Methods: We conducted a systematic review with network meta-analysis of randomized controlled trials (RCTs).
Article Synopsis
- Cardiovascular disease poses a significant risk for individuals with early chronic kidney disease (CKD), similar to that in those with coronary artery disease, prompting an updated review of statin use in CKD.
- The study evaluated randomized controlled trials (RCTs) that compare statins against placebo, no treatment, or standard care in CKD patients, focusing on outcomes like death, cardiovascular events, and kidney function.
- After analyzing 63 studies involving over 50,000 participants, the research aims to provide insights into the effectiveness and safety of statins for those with CKD not requiring dialysis.
Interventions for fatigue in people with kidney failure requiring dialysis.
Cochrane Database Syst Rev
August 2023
Background: Fatigue is a common and debilitating symptom in people receiving dialysis that is associated with an increased risk of death, cardiovascular disease and depression. Fatigue can also impair quality of life (QoL) and the ability to participate in daily activities. Fatigue has been established by patients, caregivers and health professionals as a core outcome for haemodialysis (HD).
View Article and Find Full Text PDFBackground: Erythropoiesis-stimulating agents (ESAs) are commonly used to treat anaemia in people with chronic kidney disease (CKD). However, their use has been associated with cardiovascular events. This is an update of a Cochrane review first published in 2014.
View Article and Find Full Text PDF